Henan Lingrui Pharmaceutical Co., Ltd.

600285

CNE000001501

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
24.21 ^CNY	-0.66%		-2.34%	+41.50%

May. 13	Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug	MT
Apr. 25	Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Henan Lingrui Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Year 2016

January 17, 2017

Henan Lingrui Pharmaceutical Co., Ltd. provided earnings guidance for the year 2016. The company predicts an increase of between 155% and 175% in the net profit belonging to shareholders of the listed company in 2016 compared with the same period of the year before.

Latest news about Henan Lingrui Pharmaceutical Co., Ltd.

Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug	May. 13	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China	Apr. 19	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million.	22-01-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	22-01-03	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-10-07	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-07-02	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-04-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	21-02-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	21-01-31	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-17	CI
Henan Lingrui Pharmaceutical Co., Ltd. Announces Cash Dividend for 2019, Payable on June 19, 2020	20-06-11	CI

Chart Henan Lingrui Pharmaceutical Co., Ltd.

Duration

Period

Chart Henan Lingrui Pharmaceutical Co., Ltd.

More charts

Company Profile

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Henan Lingrui Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.21

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.89B
DONG-E-E-JIAO CO.,LTD.	+37.29%	6.02B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	4.19B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	3.25B
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	2.87B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	2.37B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	1.58B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	1.54B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	1.5B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+40.06%	1.45B

Alternative Medicine